Combination drug treatment benefits patients with HIV

BMJ 1996; 313 doi: (Published 10 August 1996) Cite this as: BMJ 1996;313:320

The long awaited Delta study has confirmed that treating patients infected with HIV with a combination of zidovudine (AZT) plus either didanosine (ddI) or zalcitabine (ddC) prolongs life and delays disease progression compared with treatment with zidovudine alone. Even patients who had already treated with zidovudine found some additional benefit when didanosine was added, although the effect was less pronounced.

The international randomised double blind trial had more than 3000 participants, …

View Full Text

Log in

Log in through your institution


* For online subscription